This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Miltenyi Biotec
product type :
antibody
product name :
HLA-G Antibody, anti-human, APC-Vio® 770
catalog :
130-111-854
quantity :
100 tests in 200 µL
price :
360 USD
clonality :
monoclonal
host :
mouse
conjugate :
APC
clone name :
87G
The same clone is also sold as:
The same clone is also sold as:
- Novus Biologicals: NBP2-80772, NBP1-43123-0.1mg
- OriGene: AM03060FC-N, AM03060RP-N, AM03060BT-N
- Invitrogen: 12-9957-42, 17-9957-42, 14-9957-80, 14-9957-37, MA1-10356, 46-9957-42, MA1-10365, MA1-10361, MA1-10369, 14-9957-95, 12-9957-41, MA5-18164, 14-9957-82, 17-9957-41
- Exbio: A4-437-C100, 12-437-C100, 1F-437-C025, 11-437-C100, 1B-437-C100, 11-437-C025, A4-437-C025, 1P-437-C100, 1P-437-C025, 1B-437-C025, 1F-437-C100
- BioLegend: 335910, 335905, 335917, 335923, 335918, 335924, 335902, 335906, 335912, 335919, 335911, 335909
- Abnova: MAB5094, MAB5093, MAB11223, MAB5092
reactivity :
human
application :
flow cytometry
citations: 2
Reference |
---|
product information
MB Cataloge Number :
130-111-854
Catalog Number :
130-111-854
Product Name :
HLA-G Antibody, anti-human, APC-Vio® 770
Product Type :
Primary antibodies
Host Species :
mouse IgG2aκ
Clonality :
monoclonal
Conjugation :
APC-Vio 770
Antigen Modification :
HLA-G
Clone Name :
87G
Isotype :
Isotype Control Antibody, mouse IgG2a
Size :
100 tests in 200 µL
US List Price :
360 USD
Product Description :
Identification and enumeration of HLA-G+ cells by flow cytometry
ALTnames :
HLA G antigen, MHC class I antigen G
Specificity :
human
Concentration :
1:50
Uses :
For research use only
Application Summary :
Intracellular flow cytometry
Storage :
Store protected from light at 2–8 °C. Do not freeze.
company information
Miltenyi Biotec
Friedrich-Ebert-Strae 68
51429 Bergisch Gladbach
51429 Bergisch Gladbach
macs@miltenyibiotec.com
https://www.miltenyibiotec.com1 800 FOR MACS
headquarters: Germany
questions and comments